Table 1 Clinical characteristics of patients n=215
From: Patients’ high acceptability of a future therapeutic HIV vaccine in France: a French paradox?
Female N = 64 | Male N = 151 | Total N = 215 | |
|---|---|---|---|
Age [years] | 44 (11) | 50 (12) | 48 (12) |
Disease duration [years] | 13 (8.9) | 15 (8.9) | 14 (8.9) |
HIV infection transmission risk group | |||
Heterosexuals | 89% (54) | 27% (41) | 45% (95) |
MSM | 0% (0) | 59% (88) | 42% (88) |
Injecting drug users | 8% (5) | 11% (16) | 10% (21) |
Others | 3% (2) | 3% (5) | 3% (7) |
Duration of ART [years] | 10 (7.3) | 11 (7.0) | 11 (7.0) |
CDC clinical stage | |||
A | 60% (35) | 66% (80) | 64% (115) |
B | 12% (7) | 7% (9) | 9% (16) |
C | 28% (16) | 26% (31) | 26% (47) |
HIV viral load below detection limit | 89% (56) | 93% (138) | 92% (194) |
CD4 [cell count/mm] | 631(286) | 672 (296) | 661 (286) |
Co-morbidities | |||
Chronic hepatitis B (AgHbs+) | 8% (5) | 3% (5) | 5% (10) |
Hepatitis C (positive HCV serology) | 12% (8) | 15% (22) | 14% (30) |
HBV + HCV | 2% (1) | 1% (2) | 1% (3) |
Treated Diabetes | 3% (2) | 9% (13) | 7% (15) |
Treated Hypertension | 20% (13) | 30% (45) | 27% (58) |
Cancer | 6% (4) | 9% (13) | 8% (17) |
Vaccination coverage | |||
HBV vaccination: | |||
up to date | 64% (38) | 80% (116) | 75% (154) |
not up to date | 20% (12) | 9% (13) | 12% (25) |
don’t know | 15% (9) | 11% (16) | 12% (25) |
Diphtheria-tetanus-inactivated poliovirus vaccination dTp: | |||
up to date | 67% (43) | 75% (113) | 73% (156) |
not up to date | 14% (9) | 14% (21) | 14% (30) |
don’t know | 19% (12) | 11% (16) | 13% (28) |
Pneumococcal vaccination: | |||
updated | 16% (10) | 15% (22) | 15% (32) |
not up to date | 62% (40) | 70% (101) | 67% (141) |
don’t know | 22% (14) | 15% (22) | 17% (36) |
Influenza vaccination: | |||
up to date | 19% (12) | 23% (32) | 21% (44) |
not up to date | 72% (46) | 69% (98) | 70% (144) |
don’t know | 9% (6) | 8% (12) | 9% (18) |